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Abstract 
Disulfiram has been used for several decades in the treatment of 
alcoholism.  It now shows promise as an anti-cancer drug and 
radiosensitizer.  Proposed mechanisms of action include the induction 
of oxidative stress and inhibition of proteasome activity.  Our purpose 
was to determine the potential of disulfiram to enhance the anti-tumor 
efficacy of external beam γ-irradiation and 131I-metaiodobenzylguanidine 
(131I-MIBG), a radiopharmaceutical used for the therapy of 
neuroendocrine tumors.  Methods: The role of copper in disulfiram-
induced toxicity was investigated by clonogenic assay after treatment of 
human SK-N-BE(2c) neuroblastoma and UVW/NAT glioma cells.  
Synergistic interaction between disulfiram and radiotherapy was 
evaluated by combination index analysis.  Tumor growth delay was 
determined in vitro using multicellular tumor spheroids and in vivo using 
human tumor xenografts in athymic mice.  Results: Escalating 
disulfiram dosage caused a biphasic reduction in the surviving fraction 
of clonogens.  Clonogenic cell kill after treatment with disulfiram 
concentrations less than 4 µM was copper-dependent, whereas 
cytotoxicity at concentrations greater than 10 µM was caused by 
oxidative stress.  The cytotoxic effect of disulfiram was maximal when 
administered with equimolar copper.  Likewise, disulfiram’s 
radiosensitization of tumor cells was copper-dependent.  Furthermore, 
disulfiram treatment enhanced the toxicity of 131I-MIBG to spheroids and 
xenografts expressing the noradrenaline transporter.  Conclusions: 
The results demonstrate that (i) the cytotoxicity of disulfiram was 
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copper-dependent; (ii) molar excess of disulfiram relative to copper 
resulted in attenuation of disulfiram-mediated cytotoxicity; (iii) copper 
was required for the radiosensitizing activity of disulfiram and (iv) 
copper-complexed disulfiram enhanced the efficacy not only of external 
beam radiation but also of targeted radionuclide therapy in the form of 
131I-MIBG.  Therefore disulfiram may have anti-cancer potential in 
combination with radiotherapy. 
Keywords: disulfiram, copper, 131I-metaiodobenzylguanidine, 
neuroblastoma, radiosensitizer 
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INTRODUCTION 
Disulfiram (Antabuse), an inhibitor of aldehyde dehydrogenase (1), has been 
used for the treatment of alcoholism for several decades.  This drug also has a 
variety of other actions which suggest that it has potential as an anti-cancer 
agent.  These include the induction of oxidative stress (2,3), the generation of 
copper-dependent toxicity (2,4), proteasome inhibition (4-6), and NF-κB 
inhibition (7,8).  Despite its diverse range of pharmacological activities, 
prolonged treatment with disulfiram has negligible, reversible, adverse effects 
and is considered a safe drug (9).  Disulfiram is currently undergoing clinical 
trials for the treatment of various cancers including melanoma, liver, lung and 
prostate cancer. To determine the potential application of this agent in cancer 
therapy, it is important to understand its mechanisms of action as well as its 
effects in combination with other therapeutic modalities. 
Disulfiram-induced cytotoxicity has previously been reported to be 
mediated by oxidative stress (2,3) which may be enhanced by the presence of 
copper (2).  Copper-binding drugs have been shown to inhibit proteasome 
activity (10) and generate reactive oxygen species (ROS) (11).  Disulfiram 
chelates copper, and it may be the disulfiram-copper complex which is the 
toxic form of the drug (4).  Many tumors contain elevated levels of copper (10) 
which may render them selectively susceptible to disulfiram-induced toxicity. 
A potentially significant mechanism of disulfiram-induced cell death 
involves inhibition of proteasome activity.  The proteasome degrades 
misfolded, superfluous or damaged proteins and controls many cellular 
processes involved in differentiation, proliferation, signal transduction, cell 
cycle progression and apoptosis.  Proteasome activity is increased in cancer 
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cells compared with normal cells (12) and the proteasome inhibitor bortezomib 
is being used in the treatment of multiple myeloma.  Disulfiram has been 
reported to inhibit proteasome activity and induce apoptosis selectively in 
cancer cells, but not normal cells (4).  The copper-binding activity of 
disulfiram may also be involved in this mode of action as the formation of 
organic copper complexes appears to be responsible for pro-apoptotic 
proteasome inhibition (4).  Other proteasome inhibitors (13), including the 
reduced form of disulfiram (diethyldithiocarbamate, DDC) (14), have 
radiosensitizing effects, and this may also apply to disulfiram, further 
increasing its potential as an anti-cancer agent. 
For tumor types which are both radiosensitive and chemosensitive, such 
as neuroblastoma, combined chemotherapy and radiotherapy may offer the best 
prospects for a positive outcome to treatment.  A feature of neuroblastoma is 
expression of the noradrenaline transporter (NAT), allowing targeted 
radiotherapy using a radiolabelled structural analogue of noradrenaline, 131I-
metaiodobenzylguanidine (MIBG).  This radiopharmaceutical has proven to be 
an excellent palliative and long-term remissions have been achieved following 
single-agent treatment (15).  However, the optimal way to use 131I-MIBG has 
yet to be defined, and increasingly it is administered in combination with other 
treatments in attempts to exploit the expression of several different targets in 
the rapidly evolving cells of tumors.  Future advances in 131I-MIBG therapy are 
expected to derive from concurrent administration of radiosensitizers.  Drug 
resistance is also an important cause of failure in the treatment of 
neuroblastoma, possibly caused by increased P-glycoprotein expression after 
chemotherapy (16).  Disulfiram inhibits P-glycoprotein-mediated drug 
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resistance (17), thereby increasing sensitivity to chemotherapeutic agents and 
this approach has been used successfully for treating pediatric tumors, 
including retinoblastoma and neuroblastoma (18).  Having previously 
demonstrated synergy between the topoisomerase I inhibitor topotecan and 
131I-MIBG (19,20), we now describe the use of similar methodology to test the 
potential synergistic effect of disulfiram with 131I-MIBG treatment. 
We report an investigation of the extent to which disulfiram’s ability to 
induce cell death occurred through copper- or ROS-dependent mechanisms.  In 
the SK-N-BE(2c) and UVW/NAT cancer cell lines, clonogenic survival was 
decreased by disulfiram treatment and the presence of copper was necessary 
for tumor cell kill at low, clinically achievable, concentrations of disulfiram.  
Moreover, the molar ratio of disulfiram:copper was critical for cytotoxicity.  
Finally, a potent radiosensitizing effect of disulfiram was demonstrated in vitro 
and in vivo for the first time, and this also was copper-dependent. 
 
MATERIALS AND METHODS 
Reagents 
Disulfiram (tetraethylthiuram disulfide) was purchased from Sigma-
Aldrich (Dorset, UK) and Antabuse obtained from Actavis (Gentofte, 
Denmark).  Stock solutions of both agents were prepared in dimethyl sulfoxide 
(DMSO), then diluted in culture medium (maximum DMSO concentration 
0.1% v/v).  All other drugs were dissolved in culture medium.  All cell culture 
media and supplements were purchased from Invitrogen (Paisley, UK) and all 
other chemicals were from Sigma-Aldrich (Dorset, UK).  No-carrier-added 
131I-MIBG was prepared as described previously (20). 
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Cell Culture 
Human neuroblastoma-derived SK-N-BE(2c) cells were purchased 
from the American Type Culture Collection (Manassas, VA, USA).  The UVW 
cell line was derived from a human glioblastoma (21).  Cell lines were 
authenticated in-house using the AmpF/STR Identifiler kit (Applied 
Biosytems, Warrington, UK).  SK-N-BE(2c) cells were maintained in DMEM 
containing 15% (v/v) fetal calf serum (FCS).  UVW cells were transfected to 
express the NAT gene as previously described (22), and were maintained in 
MEM, containing 10% (v/v) FCS and 1 mg/ml geneticin at 37ºC in a 5% CO2 
atmosphere. 
 
Clonogenic Survival Assay 
Cells were seeded in 25 cm2 flasks at 105 cells/flask.  When cultures 
were in exponential growth phase, medium was removed and replaced with 
fresh medium containing disulfiram, the cell impermeable copper chelator 
bathocuproine disulfonic acid (BCPD, 300 µM), the antioxidant N-acetyl-L-
cysteine (NAC, 1mM), copper (II) chloride or various combinations of these 
agents were added simultaneously.  Cells were incubated with drugs for 24 
hours.  Cells were γ-irradiated using an Alcyon II 60Co-cobalt source at a dose-
rate of 1 Gy/min, then incubated for 24 hours.  For experiments conducted in 
serum-free conditions, cells were washed twice with PBS, before adding 
serum-free medium with or without drugs.  After drug treatment, cells were 
seeded for clonogenic assay as previously described (19,20).   
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Spheroid Growth Assay 
Multicellular spheroids were used for the evaluation of 131I-MIBG treatment 
because beta-particle cross-fire irradiation makes a considerable contribution to 
its efficacy.  This component of tumor cell kill would be under-represented in 
cellular monolayers (23). SK-N-BE(2c) and UVW/NAT cells were cultured as 
multicellular tumor spheroids using the liquid overlay technique (24).  Briefly, 
spheroids were initiated by inoculating cells into an agar-coated flask.  After 3 
to 4 days, spheroids were retrieved by centrifugation and resuspended in fresh 
serum-free culture medium containing disulfiram and/or copper for 24 h.  
Simultaneously, 131I-MIBG was added to the medium at a final concentration 
of 1 MBq/ml for SK-N-BE(2c) and 0.5 MBq/ml for UVW/NAT spheroids.  
After treatment, spheroids were washed twice and those of approximately 100 
μm in diameter were transferred individually into agar-coated wells of 24-well 
plates.  Individual spheroid growth was monitored twice per week using an 
inverted phase-contrast microscope connected to an image acquisition system.  
Two perpendicular diameters, dmax and dmin, were measured using image 
analysis software (ImageJ) and the volume, V (μm3), was calculated using the 
formula: V = π × dmax × dmin² / 6 (25). 
 
 
Combination Treatments 
The cytotoxic interaction between disulfiram and radiation was 
examined using clonogenic assay, according to the method of Chou and 
Talalay (26).  Initially, exponentially growing cells were treated with each 
agent alone to determine effective doses.  Cells were subsequently treated with 
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a range of doses of disulfiram and γ-radiation, administered simultaneously, 
using a fixed dose ratio of disulfiram to γ-radiation, so that the proportional 
contribution of each agent in the mixtures would be the same at all treatment 
intensities.  The fixed dose ratio was 0.1 µM disulfiram:0.9 Gy γ-radiation, 
based on IC50 values of 0.34 µM and 3 Gy, for disulfiram and γ-radiation, 
respectively.  The effectiveness of combinations of disulfiram and γ-radiation 
was quantified by determining a combination index (CI) at various levels of 
cytotoxicity.  As the method of interaction was unknown, CI values were 
calculated assuming both mutual exclusivity (where the drugs have similar 
mechanisms of action) and mutual non-exclusivity (where the drugs have 
dissimilar mechanisms of action).  CI < 1, CI = 1, and CI >1 indicate 
synergism, additivity, and antagonism, respectively. 
 
Tumor Xenografts 
Six-week-old female, congenitally athymic nude mice of strain CD1 
nu/nu were obtained from Charles River plc (Kent, UK).  In vivo experiments 
were carried out in accordance with the Animals (Scientific Procedures) Act 
1986.  Tumors in athymic mice formed from SK-N-BE(2c) and UVW/NAT 
cells express the NAT enabling active uptake of 131I-MIBG.  Subcutaneous 
tumor growth was established as previously described (19).  Mice were used 
for experimental therapy when the SK-N-BE(2c) tumor volumes had reached 
approximately 500 mm3 or when UVW/NAT tumors had grown to 
approximately 60 mm3.  To monitor potential toxicity, experimental animals 
were examined daily for signs of distress and weighed weekly.  Mice were 
randomized into treatment groups, each consisting of 6 animals that received: 
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PBS solution (i.p. injection); 200 mg/kg disulfiram solution (suspension in 
water, by oral gavage); 10 MBq 131I-MIBG (i.p. injection); 5 Gy γ-radiation or 
simultaneous administration of disulfiram and 131I-MIBG or disulfiram and γ-
radiation.  The activity of 131I-MIBG given to the mice was shown previously 
by us to induce significant delay of growth but incomplete sterilisation of 
UVW/NAT xenografts (19).  Tumors were measured with callipers 
immediately before treatment and twice weekly thereafter.  On the assumption 
of ellipsoidal geometry, diameter measurements were converted to an 
approximate tumor volume by multiplying half the longest diameter by the 
square of the mean of the two shorter diameters.  Mice whose xenograft 
volume reached 1,900 mm3 were euthanized. 
 
Statistics 
Data are presented as means ± standard error of the mean (SEM), 
unless otherwise stated, with the number of independent repetitions provided in 
the legend to each figure.  Statistical significance was determined using 
Student’s t test.  A P value < 0.05 was considered to be statistically significant 
and < 0.01 highly significant. 
 
RESULTS 
Disulfiram’s Cytotoxicity 
Escalating concentrations of disulfiram caused a biphasic toxicity 
profile in SK-N-BE(2c) cells (Figure 1).  Initial clonogenic kill was maximal 
after administration of 1.7 µM disulfiram.  Increasing disulfiram beyond this 
concentration resulted in partial reversal of cytotoxicity, up to 10 µM 
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disulfiram.  Thereafter, cytotoxicity increased and, following the 
administration of 17 µM disulfiram, clonogenic survival was 10% of untreated 
control levels (Fig. 1A).  The effect on clonogenic survival of the clinical 
formulation of disulfiram used in animal studies, Antabuse (Actavis), was also 
evaluated.  A concentration-dependency profile similar to that generated by 
disulfiram was observed (Fig. 1A). 
A glioma cell line transfected with the NAT gene, UVW/NAT, 
responded in an analogous manner with respect to clonogenic cell kill in 
response to a range of concentrations of disulfiram (Fig. 1B).  Again, the initial 
clonogenic survival nadir was observed following treatment with 1.7 µM 
disulfiram.  A similar biphasic dose-toxicity profile was also observed when 
UVW/NAT cells were exposed to Antabuse (Fig. 1B). 
 
Disulfiram’s Biphasic Dose-Response 
Treatment with 1 mM of the antioxidant NAC alone had no significant 
effect, but prevented the reduction in clonogenic survival of SK-N-BE(2c) cells 
and UVW/NAT cells induced by concentrations of disulfiram > 10 µM, 
whereas NAC had no significant effect on disulfiram-induced toxicity at 
concentration ≤ 10 µM (Fig. 1).  Therefore, a ROS-independent mechanism of 
cell kill predominated at low concentrations of disulfiram (≤ 10 µM). 
Although bathocuproine disulfonic acid (BCPD) alone had no 
significant effect, the disulfiram-induced reduction in clonogenic survival of 
SK-N-BE(2c) cells was prevented by BCPD, at 300 µM, in the first phase of 
the dose-response, up to and including 10 µM disulfiram, suggesting a role for 
copper in disulfiram-induced cytoxicity at low concentrations.  Although 
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UVW/NAT cells were more resistant to disulfiram, the initial, maximal, 
clonogenic cell kill observed following treatment with 1.7 µM disulfiram was 
also prevented by BCPD (Fig. 2B). 
 
Effect of Copper on Disulfiram’s Cytotoxicity 
In serum-free medium and in the absence of copper, disulfiram, at 
concentrations up to 10 µM, induced no significant reduction in survival of 
either SK-N-BE(2c) or UVW/NAT clonogens (Fig. 3), whereas the inclusion 
of copper chloride in the incubation medium resulted in dose-dependent 
clonogenic cell kill.  This was maximal when disulfiram and copper 
concentrations were equimolar (Fig. 3).  These observations suggest not only 
that the presence of copper is important for the cytotoxicity of disulfiram, but 
also that the concentration of copper relative to disulfiram is a major 
determinant of disulfiram’s potency. 
 
Copper-Dependence of Disulfiram’s Radiosensitization 
To investigate the potential for disulfiram to act as a radiosensitizer, 
SK-N-BE(2c) cells were γ-irradiated alone or in combination with disulfiram.  
A radiation dose-response was clearly demonstrated with enhancement of the 
radiation-induced clonogenic kill by disulfiram at all radiation doses (Fig. 4).  
IC50 values of 3.23 or 1.88 Gy, were observed in the absence or presence of 
disulfiram, respectively.  The effective doses of disulfiram and radiation were 
estimated from dose-responses of each agent alone.  A constant dose ratio of 
1:9 disulfiram (µM):γ-irradiation (Gy) was used in the combination 
experiments.  The combination index values were determined according to 
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Chou and Talalay (26) and are shown in Table 1.  As the manner of the 
interaction between the agents was uncertain, the formula was solved in two 
different ways, corresponding to modes of action of the two agents which are 
similar or distinct.  Synergistic kill of SK-N-BE(2c) clonogens after treatment 
with combined disulfiram and γ-irradiation was manifest by CI values < 1 for 
all dose intensities examined.  For example, at the ED30 (dose required to kill 
30% of clonogens), CI values were 0.45 ± 0.12 or 0.68 ± 0.19 assuming 
mutually exclusive or independent modes of action, respectively.  
Corresponding CI values at the ED50 were 0.62 ± 0.14, and 0.70 ± 0.19 and, at 
the ED90, 0.70 ± 0.15, and 0.80 ± 0.2.  Increasing CI values suggest decreasing 
synergism at higher dose intensities.  Nonetheless the observation of CI values 
< 1 throughout the toxicity range of the experimental combination therapy 
indicated synergy at all strengths of treatment. 
The involvement of copper in the radiosensitizing action of disulfiram 
was investigated by clonogenic assay of cells treated with combinations of 
disulfiram and γ-radiation in the presence or absence of serum, BCPD or 
copper chloride.  The clonogenic survival of γ-irradiated SK-N-BE(2c) cells 
was not significantly affected by removal of serum or incubation with BCPD or 
copper chloride.  Clonogenic cell kill resulting from treatment with 0.34 µM 
disulfiram was prevented by removal of serum (P < 0.05) or inclusion of 
BCPD (P < 0.05), and enhanced by the addition of copper chloride (P < 0.05) 
(Fig. 5).  Furthermore, the enhanced clonogenic kill induced by combined 
disulfiram and radiation treatment relative to single agent treatment was 
prevented by serum removal (P < 0.05) or addition of BCPD (P < 0.05).  In 
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contrast, incubation with copper resulted in potentiation of the cell kill 
achieved by the disulfiram and radiation combination  (P < 0.05). 
 
Effect of Disufiram and 131I-MIBG on Spheroid Growth Delay 
Copper chloride alone had no effect on the growth rate of spheroids 
composed of SK-N-BE(2c) or UVW/NAT cells, whereas disulfiram alone (at 
33.7 µM) decreased the growth rate of SK-N-BE(2c) and UVW/NAT 
spheroids.  The evaluation of a range of equimolar doses of disulfiram and 
copper indicated that treatment of spheroids with 3.37 µM induced growth 
delay but not sterilisation (data supplied but not shown - Supplemental Figure).  
Therefore 3.37 µM equimolar disulfiram/copper was the concentration used in 
subsequent evaluation of enhancement of cell kill by 131I-MIBG targeted 
radiation. 
Using relative spheroid volume on the last day of measurement as an 
index of efficacy, single agent 131I-MIBG treatment reduced spheroid growth to 
54 and 87% of control for SK-N-BE(2c) and UVW/NAT spheroids 
respectively.  Similarly disulfiram/copper reduced growth to 69% and 58% of 
control volume for SK-N-BE(2c) and UVW/NAT spheroids, respectively.  In 
contrast, combined treatment with 131I-MIBG and disulfiram/copper sterilised 
all SK-N-BE(2c) and UVW/NAT spheroids – manifest as a failure to increase 
in size throughout the 20 or 22 days’ duration of the experiments respectively 
(Fig. 6). 
 
Antitumor Activity of Disulfiram and Radiation 
The anti-tumor effect of disulfiram alone or in combination with 
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radiation treatment was studied in vivo using subcutaneous tumor xenografts 
grown in athymic mice.  None of the animals in this study showed signs of 
distress.  Alternative radiation modalities were examined – external beam γ-
rays from a 60Co-cobalt source and the NAT-seeking radiopharmaceutical 131I-
MIBG administered by intraperitoneal injection. 
Although disulfiram alone had no significant effect on tumor growth, 
the growth inhibitory effect of γ-radiation or 131I-MIBG was enhanced by 
combination treatment with disulfiram in both tumor types (Fig. 7).  The times 
after treatment for 4-fold (SK-N-BE(2c)) or 10-fold (UVW/NAT) increase in 
tumor volume (τ4 or τ10) are shown in Table 2.  These results indicate that 
combination treatment with disulfiram and radiation produced a greater tumor 
growth delay than either agent alone, and this was apparent in 2 different 
xenograft models, and using 2 different sources of radiation. 
 
DISCUSSION 
In response to treatment of neuroblastoma and glioma cells with 
disulfiram, we observed a biphasic pattern of clonogenic cell kill.  Similar 
dose-response patterns have been reported in disulfiram-treated myeloma cells 
(27), in murine leukemia cell lines incubated with the reduced form of 
disulfiram (DDC) (28) and in pheochromocytoma cells treated with the 
structurally-related compound pyrrolidine dithiocarbamate (PDTC) (29). 
It has been suggested that many of the effects of disulfiram are due to 
its ability to induce oxidative stress.  For example, disulfiram depleted 
antioxidant levels in rat cortical astrocytes (2) and elevated ROS levels in 
melanoma cells (3).  Moreover, disulfiram’s toxicity to melanoma cells was 
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prevented by exogenous antioxidants (3).  In the present study, the antioxidant 
NAC prevented the reduction in clonogenic survival induced only by high 
concentrations (> 10 µM) of disulfiram, but had no effect on disulfiram-
induced toxicity at lower concentrations.  Clinical studies have indicated that 
after a single oral dose of 500 mg, or repeated doses of 250 mg, plasma 
concentrations of disulfiram were less than 2 µM (30, 31).  Therefore, a ROS-
independent mechanism is expected to predominate at clinically achievable 
concentrations of disulfiram. 
PDTC is structurally similar to disulfiram and has been shown to cause 
serum-dependent apoptosis of breast tumor cells (32).  We also observed that 
the presence of serum was necessary for disulfiram-induced toxicity at low (< 
10 µM) disulfiram concentrations.  The toxicity of some metal-chelating 
compounds, including disulfiram, may be dependent on the presence of metal 
ions such as copper (33), and high copper concentrations have been noted in 
commercially prepared FCS (34).  Therefore, it is possible that the presence of 
copper in serum was, at least partly, responsible for the serum-dependent 
disulfiram toxicity. 
Disulfiram-induced toxicity to rat astrocytes was prevented by the cell-
impermeable copper chelator BCPD (2).  We also observed the inhibition of 
clonogenic cell kill, at disulfiram concentrations less than 10 µM, by the 
inclusion in the medium of BCPD, suggesting a role for copper in disulfiram-
induced cytotoxicity.  At concentrations of disulfiram greater than 10 µM, the 
ROS-dependent cytotoxic effect predominated.  Similarly, PDTC-induced 
apoptosis of breast cancer cells was also suggested to be a result of its copper 
binding activity (35). 
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The reduced potency of disulfiram resulting from BCPD treatment was 
similar to that observed in response to incubation with serum-free medium, 
suggesting that serum in the medium was sufficient and necessary for the 
disulfiram-induced toxicity.  The inclusion of exogenous copper in the 
incubation medium was sufficient to reinstate the toxic effect of disulfiram in 
the absence of serum, whereas BCPD, in molar excess relative to disulfiram, 
prevented the toxic effect of copper, presumably by competing with disulfiram 
for extracellular copper binding. 
Clonogenic cell kill was maximal when disulfiram and copper 
concentrations were equimolar.  Increasing concentration of disulfiram in 
molar excess of copper progressively reduced the cytotoxic effect of the 
disulfiram-copper complex.  This suggests that the concentration of copper 
relative to disulfiram is crucial with respect to cytotoxicity. 
The increased potency of disulfiram observed in the presence of serum 
may also be explained by copper chelation.  Serum contains approximately 15 
µM copper (36).  Therefore cells cultured in 10 or 15% (v/v) serum would be 
exposed to 1.5 or 2.3 µM copper.  In serum-containing medium, the greatest 
cell kill resulting from disulfiram treatment occurred at 1.7 µM.  This 
observation is consistent with the requirement for copper chelation for optimal 
effectiveness of disulfiram.  It also suggests that there would be sufficient 
copper in human and murine serum to allow the formation of effective levels of 
the disulfiram-copper complex. 
Similarly, it has been observed that the toxicity of disulfiram to 
Salmonella typhimurium was increased by the elevation of copper sulphate 
levels to equimolar concentration, but was decreased in the presence of excess 
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disulfiram (37).  The presence of surplus disulfiram may result in competition 
between free disulfiram and disulfiram-copper complexes for cellular uptake or 
intracellular binding.  This competition for targets may then explain the effect 
of increasing survival observed with increasing disulfiram concentration above 
copper concentration. 
The dithiocarbamates disulfiram and PDTC have been reported to be 
effective inhibitors of proteasome activity (5) especially when complexed with 
copper (6).  Because the proteasome plays a pivotal role in the control of cell cycle 
progression and survival after potentially toxic insult, proteasome inhibitors are 
regarded as promising anti-cancer agents.  They can induce apoptosis as a 
consequence of the accumulation of undegraded proteins and the prevention of NF-
κB activation.  Disulfiram also facilitates copper uptake (33), increasing its 
intracellular availability.  Therefore, it appears that disulfiram has potential as an 
anti-cancer agent.  In particular, the absence of anti-tumor effect by disulfiram 
administered as a single agent as opposed to its enhancement of radiotoxicity 
suggests that disulfiram’s efficacy should be characterized by tumor specificity and 
minimal damage to tissues which fail to accumulate radiopharmaceutical. 
It has been suggested that proteasome inhibitors may be effective 
radiosensitizers (13).  Therefore it is possible that disulfiram or its metabolites 
have radiosensitizing properties.  Indeed, DDC has previously been shown to 
enhance radiation sensitivity in rapidly proliferating cells (14).  We observed 
that disulfiram acted synergistically with γ-radiation to potentiate clonogenic 
cell kill at all levels of toxicity.  The clonogenic survival of cells exposed to γ-
radiation was not affected by removal of serum or the addition of BCPD or 
copper(II) chloride, indicating that radiation-induced clonogenic cell kill was 
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not copper-dependent.  Conversely, clonogenic cell kill by disulfiram at 0.34 
µM, a concentration previously shown to inhibit proteasome activity in cell-
based assays (5), was prevented by removal of serum or addition of BCPD and 
enhanced by copper supplementation.  Moreover, the enhanced clonogenic cell 
kill resulting from combined disulfiram and γ-radiation treatment was 
prevented by serum removal or incubation with BCPD, whereas the addition of 
copper reinstated the toxicity of γ-radiation combined with disulfiram in 
serum-free conditions.  This suggests that copper was necessary for 
radiosensitization by disulfiram. 
We have demonstrated in vitro, and for the first time in vivo, that 
disulfiram acted as a radiosensitizer.  The effect of disulfiram alone was less 
appreciable in spheroids compared with monolayers.  Resistance associated 
with aggregates of cells is a commonly observed effect and has been attributed 
to intercellular linkage, interactions between cell and matrix and limited 
penetration resulting in gradients of oxygen, nutrients and drugs (38).  
Disulfiram did, however, enhance the radiation-induced delay of the growth of 
spheroids derived from two different tumor cell lines and retarded the growth 
of two human tumor xenografts in athymic mice.  Not only did disulfiram 
enhance the anti-tumor efficacy of γ-radiation delivered from an external 
source, but it also potentiated the efficacy of 131I-MIBG targeted radionuclide 
therapy, in both spheroid and xenograft models.  Significantly, the synergistic 
activity in vivo was achieved at a disulfiram dosage which had negligible effect 
on xenograft tumor growth and which has previously been demonstrated to be 
associated with insignificant side effects (9).  Such features are highly desirable 
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in a radiosensitizing agent (39).  The positive interaction between disulfiram 
and 131I-MIBG is worthy of further investigation. 
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FIGURE LEGENDS 
 
FIGURE 1.  Cytotoxicity of disulfiram is biphasic with respect to dose. 
Clonogenic survival after exposure of (A) SK-N-BE(2c) cells or (B) 
UVW/NAT cells to disulfiram for 24 h in the absence or presence of 
NAC, or to the clinical formulation of disulfiram (Antabuse); n = 4.  Data 
are means ± SEM; significance of differences: * p<0.05, ** p<0.01 from 
untreated control, † p<0.05 from disulfiram alone.  Abbreviations: DSF 
(disulfiram) and NAC (N-acetyl-L-cysteine). 
 
FIGURE 2.  Copper is necessary for toxicity of disulfiram at 
concentrations < 4 µM.  Clonogenic survival after exposure of (A) SK-N-
BE(2c) cells or (B) UVW/NAT cells to disulfiram for 24 h in the absence 
or presence of BCPD; n = 5.  Data are means ± SEM; significance of 
differences: * p<0.05, ** p<0.01 from untreated control, † p<0.05 from 
disulfiram alone. Abbreviation: BCPD (bathocuproine disulfonic acid). 
 
FIGURE 3.  Clonogenic cell kill is dependent on the relative 
concentrations of disulfiram and copper.  Clonogenic survival after 
exposure of (A) SK-N-BE(2c) cells or (B) UVW/NAT cells to disulfiram 
for 24 h in the absence or presence of CuCl2 in serum-free medium; n = 
4.  Data are means ± SEM; significance of differences from untreated 
controls: * p<0.05, ** p<0.01. 
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Figure 4. Effect of disulfiram on radiosensitivity of SK-N-BE(2c) cells.  
Clonogenic survival was determined after exposure of cells to γ-radiation 
alone or simultaneously with 0.34 mM disulfiram (n=4) after correcting for 
plating efficiency and disulfiram cytotoxicity alone. Data are means ± SEM. 
Abbreviation: DSF (disulfiram). 
 
FIGURE 5.  Enhancement of radiation cell kill by disulfiram requires 
copper.   
Clonogenic survival after exposure of SK-N-BE(2c) cells to 0.34 µM 
disulfiram, 3 Gy γ-radiation, or a combination of both treatments in (1) 
serum-containing medium, (2) serum-containing medium with 300 µM 
BCPD, (3) serum-free medium, or (4) serum-free medium containing 1 
µM CuCl2; n=3.  Data are means ± SEM; significance of differences: * 
p<0.05, ** p<0.01 from untreated control, † p<0.05, †† p<0.01 from γ-
irradiation alone.  Abbreviations: DSF (disulfiram) and BCPD 
(bathocuproine disulfonic acid). 
 
FIGURE 6.  Disulfiram enhances the delay of spheroid growth induced 
by 131I-MIBG.  Multiceullar spheroids derived from (A) SK-N-BE(2c) or 
(B) UVW/NAT cells were treated with disulfiram + CuCl2 (3.37 µM), 131I-
MIBG (1 MBq/ml for SK-N-BE(2c), 0.5 MBq/ml for UVW/NAT), or a 
combination of both.  Data are expressed as mean spheroid volume at 
every time point divided by original volume (V/V0) ± SD of 13 to 23 
spheroids per treatment.  Abbreviation: DSF (disulfiram). 
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FIGURE 7.  Disufiram enhances radiation-induced growth delay of 
experimental tumors.  Growth of human tumor xenografts in athymic 
mice exposed to PBS, disulfiram alone (200 mg/kg), γ-radiation (5 Gy), 
131I-MIBG (10 MBq), or combinations of disulfiram with γ-radiation or 
131I-MIBG.  Xenografts were derived from (A) SK-N-BE(2c) or (B) 
UVW/NAT cells.  Data are expressed as mean tumor volume at every 
time point divided by original volume (V/V0) ± SD.  Abbreviation: DSF 
(disulfiram). 
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TABLE 1 
The effect of disulfiram and γ-radiation on combination indices 
 Effect level  Mutually exclusive  Mutually non-exclusive 
 
ED30 0.45 ± 0.12 0.68 ± 0.19 
ED40 0.61 ± 0.14 0.69 ± 0.19 
ED50 0.62 ± 0.14 0.70 ± 0.19 
ED70 0.64 ± 0.14 0.73 ± 0.20 
ED90 0.70 ± 0.15 0.80 ± 0.21 
 
Combination index values are means ± SEM of 4 experiments. 
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TABLE 2 
The effect of single agent or combination treatment on tumor growth 
Treatment τ4 - SK-N-BE(2c) τ10 - UVW/NAT 
 (days) (days) 
 
PBS 20.7 17.4 
DSF† 25.5 18.9 
γ-radiation 34.2 27.9 
131I-MIBG 39.1 31.5 
DSF + γ-radiation 54.0 45.3 
DSF + 131I-MIBG 57.6 47.2 
 
The effect of treatment on the time taken for 4-fold or 10-fold increases (τ4 or τ10) in 
volume of tumors derived from SK-N-BE(2c) and UVW/NAT cells respectively.  Data 
are means of 6 xenografts per treatment. 
†Abbreviation: DSF (disulfiram). 
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